Neuroimaging-genetic paradigms: A new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia

被引:37
|
作者
Roffman, JL
Weiss, AP
Goff, DC
Rauch, SL
Weinberger, DR
机构
[1] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA
[2] Harvard Univ, Sch Med, Charlestown, MA 02129 USA
[3] NIMH, Genes Cognit & Psychosis Program, NIH, Bethesda, MD 20892 USA
关键词
cognitive impairment; genetics; neuroimaging; schizophrenia;
D O I
10.1080/10673220600642945
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Cognitive impairment is a prominent and debilitating feature of schizophrenia. Genetic predisposition likely accounts for a large proportion of these cognitive deficits. Direct associations between candidate genes and cognitive dysfunction have been difficult to establish, however, largely due to the subtle effects of these genes on observable behavior. Neuroimaging techniques can provide a sensitive means to bridge the neurobiology of genes and behavior. Here we illustrate the use of neuroimaging-genetics paradigms to elaborate the relationship between genes and cognitive dysfunction in schizophrenia. After reviewing principles important for the selection of genes, neuroimaging techniques, and subjects, we describe how imaging-genetics investigations have helped clarify the contribution of five candidate genes (COMT, GRM3, G72, DISC1, and BDNF) to cognitive deficits in schizophrenia. The potential of this approach for improving patient care will depend on its ability to predict outcomes with greater accuracy and sensitivity than current clinical measures.
引用
收藏
页码:78 / 91
页数:14
相关论文
共 50 条
  • [21] Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates
    Vita, Antonio
    Minelli, Alessandra
    Barlati, Stefano
    Deste, Giacomo
    Giacopuzzi, Edoardo
    Valsecchi, Paolo
    Turrina, Cesare
    Gennarelli, Massimo
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [22] Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment
    Javitt, Daniel C.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2023, 63 : 119 - 141
  • [23] The Genetic Architecture of Schizophrenia: New Mutations and Emerging Paradigms
    Rodriguez-Murillo, Laura
    Gogos, Joseph A.
    Karayiorgou, Maria
    ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 : 63 - 80
  • [24] THE GENETIC ARCHITECTURE OF SCHIZOPHRENIA: NEW MUTATIONS AND EMERGING PARADIGMS
    Karayiorgou, Maria
    SCHIZOPHRENIA RESEARCH, 2012, 136 : S27 - S27
  • [25] Specific cognitive deficits in a group at genetic high risk of schizophrenia
    O'Connor, M.
    Harris, J. M.
    McIntosh, A. M.
    Owens, D. G. C.
    Lawrie, S. M.
    Johnstone, E. C.
    PSYCHOLOGICAL MEDICINE, 2009, 39 (10) : 1649 - 1655
  • [26] Treatment of cognitive deficits in schizophrenia with atomoxetine: A case report
    Rao, Naren P.
    Venkatasubramanian, Ganesan
    Gangadhar, Bangalore N.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) : 1988 - 1989
  • [27] Novel leads in the treatment of schizophrenia with focus on cognitive deficits
    Svensson, T
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 15 - 15
  • [28] Psychopharmacological treatment of cognitive deficits in Schizophrenia and mood disorders
    Vita, A.
    Mussoni, C.
    Deste, G.
    Ferlenghi, G.
    Turrina, C.
    Valsecchi, P.
    JOURNAL OF PSYCHOPATHOLOGY, 2018, 24 (02): : 62 - 72
  • [29] Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment
    Chabrol, H
    Peresson, G
    Bonnet, D
    AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (03): : 497 - 497
  • [30] NEW NEUROSCIENCE BASED COGNITIVE PARADIGMS FOR BIOMARKER RESEARCH IN SCHIZOPHRENIA
    Barch, Deanna M.
    Carter, C. S.
    Gold, J.
    Harms, M.
    MacDonald, A.
    Poppe, A.
    Ragland, J. D.
    Silverstein, S.
    Strauss, M. E.
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S13 - S13